Abstract
Background: Hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery. The typical histopathological changes that occur in these tumoral masses are described in a series of 30 patients.
Methods: Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-α plus melphalan. The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels.
Results: The typical histological changes were central cystic hemorrhagic necrosis with pericystic extensive fibrosis. Some nonspecific changes were noted in the soft tissues around the mass. In eight cases, more than 90% necrosis was found. In 17 cases, the extent of necrosis ranged between 60% and 90% (80%–90% in 4 of 17 cases). In five cases, less than 60% necrosis was noted. The best responses (.90% necrosis) were observed in distally located tumors. The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma. Desmoid tumors showed less necrosis than high grade sarcomas. Vascular invasion was observed in two cases and intralesional venous thrombosis in one case. No perineural invasion or lymph nodes involvement were observed. The soft tissues adjacent to the tumor bed did not show major morphological changes. No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size.
Conclusions: This is the first serial histological description of the effects of tumor necrosis factor-α and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas. The small number of specimens and, especially, the variability of tumors preclude definite conclusions. Larger numbers and more homogeneity are needed in future studies.
This is a preview of subscription content, log in via an institution to check access.
References
Asher AL, Mule JY, Reichert CM, Shiloni E, Rosenberg SA. Studies of the antitumor efficacy of systematically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963–974.
Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-a and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results .90% response rate and limb preservation. Cancer 1997;79:1129–1137.
Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039–1044.
Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740–755.
Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of TNF on tumor vasculature in mice. Cancer Res 1988;49:2179–2183.
Folli S, Pelegrin A, Chalandon Y, et al. Tumor necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993;53:829–835.
Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987;5:1942–1951.
Rosenberg SA, Suit HD, Barker LH. Sarcomas of soft tissue. In: Devita VT., Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1993:1436–1488.
Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470–473.
Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52–60.
Eggermont AMM, Schraffordt Koops H, et al. Isolated limb perfusion with high-dose tumor necrosis factor ain combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: a multicentric trial. J Clin Oncol 1996;14:2653–2657.
Huvos A. Bone Tumors: Diagnosis, Treatment and Prognosis. Philadelphia: WB Saunders, 1991.
Carper ES, Gaynor JJ, Harrison LB, et al. Preoperative and postoperative adjuvant chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994;73:1644–1648.
Pezzi GM, Pollock RE, Evans HL, et al. Preoperative chemotherapy for soft tissue sarcoma of the extremities. Ann Surg 1990;211:476–481.
Drory VE, Lev D, Groozman GB, Gutman M, Klausner JM. Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurol Sci 1998;158:1–4.
Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987;60:1703–1707.
Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumor necrosis factor. Brain 1995;118:869–878.
Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb Cancer by isolation perfusion with high dose alpha tumor necrosis factor, gamma interferon, and melphalan. Cancer 1994;73:483–492.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Issakov, J., Merimsky, O., Gutman, M. et al. Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor-α and Melphalan in Advanced Soft-Tissue Sarcomas: Histopathological Considerations. Ann Surg Oncol 7, 155–159 (2000). https://doi.org/10.1007/s10434-000-0155-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0155-1